Inhaled Milrinone After Left Ventricular Assist Device聽Implantation

详细信息    查看全文

• 作者：Nicholas A. Haglund ; MD¹ ; ^{nicholas.a.haglund@vanderbilt.edu" class="auth_mail" title="E-mail the corresponding author} ; Adam Burdorf ; DO¹ ; Tara Jones ; MD¹ ; Valerie Shostrom ; MS¹ ; John Um ; MD² ; Timothy Ryan ; APRN ; NP² ; Sasha Shillcutt ; MD³ ; Patricia Fischer ; RN¹ ; Zachary L. Cox ; PharmD⁴ ; Eugenia Raichlin ; MD¹ ; Brian D. Lowes ; MD PhD¹ ; Ioana Dumitru ; MD¹
• 关键词：Phosphodiesterase inhibitor ; nebulization ; right ventricular dysfunction ; left ventricular assist device
• 刊名：Journal of Cardiac Failure
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：21
• 期：10
• 页码：792-797
• 全文大小：186 K

文摘

Proven strategies to reduce right ventricular (RV) dysfunction after continuous-flow left ventricular assist device (CF-LVAD) implantation are lacking. We sought to evaluate the tolerability, feasibility, efficacy, and pharmacokinetics of inhaled milrinone (iMil) delivery after CF-LVAD implantation.

Methods and Results

We prospectively evaluated fixed-dose nebulized iMil delivered into a ventilator circuit for 24 hours in 10 postoperative CF-LVAD (Heartmate-II) patients. Tolerability (arrhythmias, hypotension, and hypersensitivity reaction), efficacy (hemodynamics), pharmacokinetics (plasma milrinone levels), and cost data were collected.Mean age was 56 ± 9 years, 90% were male, and mean INTERMACS profile was 2.5 ± 0.8. No new atrial arrhythmia events occurred, although 3 (30%) ventricular tachycardia (1 nonsustained, 2 sustained) events occurred. Sustained hypotension, drug hypersensitivity, death, or need for right ventricular assist device were not observed. Invasive mean pulmonary arterial pressure from baseline to during iMil therapy was improved (P = .017). Mean plasma milrinone levels (ng/mL) at baseline, and 1, 4, 8, 12, and 24 hours were 74.2 ± 35.4, 111.3 ± 70.9, 135.9 ± 41.5, 205.0 ± 86.7, 176.8 ± 61.3 187.6 ± 105.5, respectively. Reduced institutional cost was observed when iMil was compared with nitric oxide therapy over 24 hours ($165.29 vs $1,944.00, respectively).

Conclusions

iMil delivery after CF-LVAD implantation was well tolerated, feasible, and demonstrated favorable hemodynamic, pharmacokinetic, and cost profiles. iMil therapy warrants further study in larger clinical trials.